
|Articles|October 1, 2003
Platinum-based chemo shows modest benefit in bladder Ca
Chicago-Neoadjuvant platinum-based chemotherapy is associatedwith a statistically significant improvement in the overall survival ofpatients with locally advanced bladder cancer, according to the resultsof a recent meta-analysis presented at the AUA annual meeting here. However,the treatment benefit is not strong enough to support a recommendation forusing neoadjuvant chemotherapy in this setting, said Amir Sherif, MD, PhD,speaking on behalf of the Nordic Cooperative Bladder Cancer Group.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
3
Choosing salvage therapy after prostate cancer focal ablation
4
NDV-01 produces robust 9-month results in high-risk NMIBC
5


















